Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?
- PMID: 40758773
- DOI: 10.1161/CIRCULATIONAHA.125.075816
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?
Keywords: Editorials; anticoagulants; atrial fibrillation; hemorrhage.
Conflict of interest statement
Dr Steg has received research grants from Amarin, AstraZeneca, and Sanofi; funds for clinical trials, consulting, or speaking from Amarin, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Janssen, Novartis, Novo-Nordisk, PhaseBio, Pfizer, and Sanofi; and is a Senior Associate Editor at
Comment on
-
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.Circulation. 2025 Aug 5;152(5):290-296. doi: 10.1161/CIRCULATIONAHA.125.074037. Epub 2025 Jun 23. Circulation. 2025. PMID: 40546068 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
